Gilead Sciences, Inc. is a Delaware-incorporated biopharmaceutical company headquartered in Foster City, California, whose marketed products include HIV therapies (BIKTARVY, DESCOVY, SUNLENCA), oncology cell therapies (YESCARTA, TECARTUS), hepatitis treatments, and other antiviral and specialty medicines. The company is listed on the Nasdaq Global Select Market under the ticker GILD and reported total assets of $59,023 million as of December 31, 2025. On February 22, 2026, Gilead entered into a definitive merger agreement to acquire Arcellx, Inc. through a cash tender offer.

What is GILD's DredgeCap risk score?

DredgeCap's AI analysis rates GILD at 3.2/10 on the risk scale — Low risk. This score reflects dilution exposure, debt toxicity, liquidity position, and going-concern posture as disclosed in SEC filings.

Does GILD have a going concern warning?

No current auditor going-concern warning is flagged in GILD's SEC filings. Risk assessment is based on other filing-disclosed factors.

When did GILD last file with the SEC?

GILD's most recent SEC filing was a 10-K filed 2026-02-24. All filings are available on SEC EDGAR.

← GILD Overview

10-QMay 7, 2026· Quarter Ended March 31, 2026

GILD — 10-Q Filing

Track GILD for Alerts

GILD 10-Q Summary

For the quarter ended March 31, 2026, Gilead Sciences, Inc. reported revenue of $6.96B, up 4.4% year-over-year. Operating income was $2.59B, up 15.6% year-over-year; net income was $2.02B, up 53.7% year-over-year. Diluted earnings per share came in at $1.61, compared to $1.04 in the prior-year quarter.

GILD Financial Highlights

Metric

Q-End 03/26

Q-End 03/25

Revenue

$6.96B

$6.67B

▲+4.4% YoY

Operating Income

$2.59B

$2.24B

▲+15.6% YoY

Net Income

$2.02B

$1.31B

▲+53.7% YoY

EPS (Diluted)

$1.61

$1.04

▲+54.8% YoY

EPS (Basic)

$1.63

$1.06

▲+53.8% YoY

Current DredgeCap Risk Profile

Risk Score

3.2/10

MODERATE

Dilution

1.8

Debt Toxicity

3.5

Going Concern

✓ Not flagged

The risk profile above reflects the latest cached DredgeCap analysis for GILD. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open GILD's company page.

What is a 10-Q?

A quarterly report covering the three months just ended. Includes unaudited condensed financial statements (balance sheet, income statement, cash flow), Management Discussion and Analysis (MD&A), and disclosure of material changes since the last annual report. Required for the first three fiscal quarters; the fourth quarter is rolled into the 10-K.

More on GILD

Financial highlights are sourced directly from the 10-Q income statement (three months ended). YoY % compares to the same quarter one year earlier as reported by the issuer. The plain-language summary above is composed mechanically from the filing's reported numbers — no analysis or opinion. Form-type explainers and 8-K item descriptions are derived from SEC documentation. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.